Literature DB >> 16855847

Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?

Friedrich C Luft1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16855847     DOI： 10.1007/s00109-006-0071-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  7 in total

1.  Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

Authors:  S M Boekholdt; F M Sacks; J W Jukema; J Shepherd; D J Freeman; A D McMahon; F Cambien; V Nicaud; G J de Grooth; P J Talmud; S E Humphries; G J Miller; G Eiriksdottir; V Gudnason; H Kauma; S Kakko; M J Savolainen; M Arca; A Montali; S Liu; H J Lanz; A H Zwinderman; J A Kuivenhoven; J J P Kastelein
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

2.  Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.

Authors:  Greetje J de Grooth; Jan Albert Kuivenhoven; Anton F H Stalenhoef; Jacqueline de Graaf; Aeilko H Zwinderman; Jan L Posma; Arie van Tol; John J P Kastelein
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

3.  The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease.

Authors:  Jeffrey Rhyne; Michael J Ryan; Charles White; Theodore Chimonas; Michael Miller
Journal:  J Mol Med (Berl)       Date:  2006-07-20       Impact factor: 4.599

Review 4.  Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.

Authors:  James S Forrester; Rajenda Makkar; P K Shah
Journal:  Circulation       Date:  2005-04-12       Impact factor: 29.690

5.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

Authors:  S Zhong; D S Sharp; J S Grove; C Bruce; K Yano; J D Curb; A R Tall
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

6.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.

Authors:  Fumihiko Matsuura; Nan Wang; Wengen Chen; Xian-Cheng Jiang; Alan R Tall
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Putting cholesterol in its place: apoE and reverse cholesterol transport.

Authors:  Robert W Mahley; Yadong Huang; Karl H Weisgraber
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.